Finally, to assess long-term toxicity, the researchers followed mice that received CARD11-PIK3R3 T cell therapies, including those that were part of the dose-response study, for up to 418 days.

Mice normally live about two years, and research found the uPAR-targeting CAR T cells persisted and expanded for more than 15 months in mice as they grew from youth into older age.